Study S000703
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin
Registration
Registered primary outcomes
- Change in HbA1c From Baseline to Week 28 [Baseline to Week 28]
Linked records (3)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0013562 | Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Guja C, Diabetes therapy : research, treatment and education of diabetes and related disorders | 2020 | Other trial | PMID 32306296DOI | cites ClinicalTrials.gov:NCT02229383; registry reference DERIVED:32306296 |
| R0014763 | Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Guja C, Diabetes, obesity & metabolism | 2018 | Randomized trial | PMID 29473704DOI | cites ClinicalTrials.gov:NCT02229383; registry reference DERIVED:29473704 |
| R0053153 | Wirksamkeit und Verträglichkeit von Depot-Exenatide gegenüber Placebo als Add-on zu Insulin glargin bei Typ-2-Diabetes-Patienten mit unzureichender glykämischer Kontrolle unter Basalinsulin: Duration-7-Studie JP Frias, Diabetologie und Stoffwechsel | 2018 | Other | DOI | cites ClinicalTrials.gov:NCT02229383 |